Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

VERU INC.

VERU · Nasdaq · CIK 0000863894 · Healthcare · Biotechnology

INSIDER SIGNAL

39.1 / 100

1 buyers · 1 purchase transaction lines · $4.8K gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeLow
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+7.0 / 35
Purchase size+0.9 / 25
Role+18.0 / 20
Recency+3.3 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 1 insider(s), not 4+
  • ⚠ Purchase size is modest relative to the model scale
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Chief Scientific Officer

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS1
PURCHASE CONCENTRATION100%Largest buyer: BARNETTE K GARY · $4.8K
CLUSTER BUYING · 15D1 insiderPeak activity: 2026-08-13–2026-08-13

Roles in the peak window: Chief Scientific Officer. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
BARNETTE K GARYChief Scientific Officer
●
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

39.1 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 39.4
  2. 39.4
  3. 39.3
  4. 39.2
  5. 39.1

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

1Purchases
0Sales
0Other Form 4 lines
1SEC filings · 365 days
BUYING1 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER0 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-1.6%
3M
-3.9%
6M
+3.4%
12M
-44.2%

Volatility & liquidity

Volatility
105.1%
Beta
—
Avg daily value
USD 587,979

Valuation

Market cap
USD 41.9M
P/E
—

Fundamentals

Profit margin
—
ROE
-124.0%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, ROE · Fiscal year ended: 2025-09-30 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-06 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
1,402,996
Previous report
1,506,493
Avg daily volume
110,348
Days to cover
12.7

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-13BARNETTE K GARYPurchase (P)Common Stock1,800USD 2.69USD 4,842SEC filing ↗
2025-02-19Rankowitz Michael LPurchase (P)Common Stock54,721USD 0.58USD 31,738SEC filing ↗
2025-02-18Rankowitz Michael LPurchase (P)Common Stock95,279USD 0.55USD 52,403SEC filing ↗
2024-05-24FISCH HARRYPurchase (P)Common Stock4,000USD 1.25USD 5,000SEC filing ↗
2024-05-24BARNETTE K GARYPurchase (P)Common Stock5,000USD 1.34USD 6,700SEC filing ↗
2024-05-15FISCH HARRYPurchase (P)Common Stock6,711USD 1.49USD 9,999SEC filing ↗
2021-08-17Lu LucyPurchase (P)Common Stock4,800USD 6.78USD 32,544SEC filing ↗
2021-03-10Hyun GracePurchase (P)Common Stock3,500USD 14.09USD 49,315SEC filing ↗
2020-08-26FISCH HARRYPurchase (P)Common Stock5,000USD 2.76USD 13,800SEC filing ↗
2020-08-24Greco MichelePurchase (P)Common Stock5,000USD 2.65USD 13,250SEC filing ↗
2020-02-21FISCH HARRYPurchase (P)Common Stock1,000USD 4.47USD 4,470SEC filing ↗
2020-02-20FISCH HARRYPurchase (P)Common Stock1,000USD 4.51USD 4,510SEC filing ↗
2020-02-19Socorro JesusPurchase (P)Common Stock5,000USD 4.27USD 21,350SEC filing ↗

Form 4 evidence

1 transaction lines in the latest 365-day window; 28 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-13BARNETTE K GARYPurchase (P)Common Stock1,800USD 2.69USD 4,842SEC filing ↗
Show recent Form 4 evidence (1 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-13BARNETTE K GARYPurchase (P)Common Stock1,800USD 2.69USD 4,842SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerVERU
CIK0000863894
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history28 transaction lines from 2020-02-19 to 2026-08-13
13 P purchase lines · 11 S sale lines · 4 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.